---
title: Comparative Assessment of the Clinical Utility of Ovarian Stimulation With Menotropin Versus Menotropin Plus GnRH Antagonist
nct_id: NCT01331733
overall_status: COMPLETED
sponsor: Ferring Pharmaceuticals
study_type: OBSERVATIONAL
primary_condition: Sterility
countries: Spain
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01331733.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01331733"
ct_last_update_post_date: 2011-04-08
last_seen_at: "2026-05-12T06:42:34.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Comparative Assessment of the Clinical Utility of Ovarian Stimulation With Menotropin Versus Menotropin Plus GnRH Antagonist

**Official Title:** Comparative Assessment of the Clinical Utility of Ovarian Stimulation With Menotropin Versus Menotropin Plus GnRH Antagonist Following Two Protocols of Ovulation Induction for Intrauterine Insemination

**NCT ID:** [NCT01331733](https://clinicaltrials.gov/study/NCT01331733)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 131
- **Lead Sponsor:** Ferring Pharmaceuticals
- **Collaborators:** Ferring SAU
- **Conditions:** Sterility
- **Start Date:** 2006-11
- **Completion Date:** 2009-03
- **CT.gov Last Update:** 2011-04-08

## Brief Summary

To assess the effectiveness of protocols of ovarian hyperstimulation combining urinary gonadotrophins + GnRH antagonist vs urinary gonadotrophins, to achieve clinical pregnancy in females undergoing intrauterine insemination.

Study hypothesis: protocols combining urinary gonadotrophins + GnRH antagonist should be more effective than monotherapy.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 36 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Women aged 18-36 years
* Body mass index (BMI) between 18 and 26
* Prolactin within the laboratory normal range
* Couples affected by sterility able to treat by IUI (intrauterine insemination)
* Patients undergoing Menopur® treatment
* Normal thyroid function
* Regular menses (21-35 days)
* Couples willing to participate in the study that have signed the informed consent form
* Seminal sample REM\>3 million

Exclusion Criteria:

* Two previous ART (assisted reproductive technology) cycles without ongoing pregnancy
* Policystic ovarian syndrome
* Evidence of significant bacterial infection in the seminogram of the couple in the preceding 6 months
```

## Arms

- **hMG-HP** — Patients with a condition
- **hMG-HP + GnRH antagonist** — Patients with a condition

## Interventions

- **hMG-HP** (DRUG)
- **hMG + GnRH antagonist** (DRUG)

## Primary Outcomes

- **Clinical pregnancy rate** _(time frame: 30 days)_

## Secondary Outcomes

- **Live birth rate** _(time frame: 40 weeks)_

## Locations (7)

- Investigational site, Barcelona, Barcelona, Spain
- Investigational site, Ciudad Real, Ciudad Real, Spain
- Investigational site, Girona, Gerona, Spain
- Investigational site, La Rioja, La Rioja, Spain
- Investigational site, Navarra, Navarre, Spain
- Investigational site, Reus, Tarragona, Spain
- Investigational site, Valladolid, Valladolid, Spain

## Recent Field Changes (last 30 days)

- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.investigational site|barcelona|barcelona|spain` — added _(2026-05-12)_
- `locations.investigational site|ciudad real|ciudad real|spain` — added _(2026-05-12)_
- `locations.investigational site|girona|gerona|spain` — added _(2026-05-12)_
- `locations.investigational site|la rioja|la rioja|spain` — added _(2026-05-12)_
- `locations.investigational site|navarra|navarre|spain` — added _(2026-05-12)_
- `locations.investigational site|reus|tarragona|spain` — added _(2026-05-12)_
- `locations.investigational site|valladolid|valladolid|spain` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01331733.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01331733*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*